Article
eDiary collected patient results for approved drug
Pittsburgh-When the FDA recently approved ketorolac tromethamine ophthalmic solution (Acular LS 0.4%, Allergan), history was made on several fronts. Not only was it a banner day for Allergan, whose solution won approval, but it represented the first time an electronic patient diary was used to collect and tabulate primary efficacy data for a phase III pivotal trial.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
